Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.71 |
| ▸ | PPARG | P37231 | 13/20 | 0.71 |
| ▸ | PPARD | Q03181 | 10/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11432241 | 0.91 | FFAR1 (0.65) | PPARAPPARGPPARDFFAR1LTA4H | |
| SCHEMBL5381390 | 0.84 | PPARG (0.77) | PPARAPPARGPPARDSLC2A1 | |
| SCHEMBL5381399 | 0.84 | PPARG (0.77) | PPARAPPARGPPARDSLC2A1 | |
| Hydrochloric Acid SCHEMBL10818791 | 0.84 | PPARD (0.55) | PPARAPPARGPPARDACACB | |
| Naveglitazar SCHEMBL5374978 | 0.83 | PPARG (1.00) | PPARAPPARGPPARD | |
| Naveglitazar SCHEMBL677199 | 0.83 | PPARG (1.00) | PPARAPPARGPPARD | |
| Naveglitazar SCHEMBL2827844 | 0.83 | PPARG (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5383389 | 0.83 | PPARG (0.75) | PPARAPPARGPPARDSLC2A1 | |
| Naveglitazar SCHEMBL5383187 | 0.82 | PPARG (0.97) | PPARAPPARGPPARD | |
| SCHEMBL5379904 | 0.82 | PPARG (0.78) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.